About Sellas

SELLAS LIFE SCIENCES IS A LATE-STAGE CLINICAL BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL CANCER IMMUNOTHERAPIES FOR A BROAD RANGE OF CANCER INDICATIONS.

SELLAS’ lead product candidate, galinpepimut-S (GPS), licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The WT1 antigen is one of the most widely expressed cancer antigens and is ranked by the National Cancer Institute (NCI) as the top priority among cancer antigens for immunotherapy. Traditional approaches have not yet been proven to successfully address the WT1 protein, as WT1 is not druggable with small molecules and is intracellular and inaccessible to antibodies.

In January 2020, SELLAS commenced a pivotal Phase 3 study of GPS in acute myeloid leukemia (AML). SELLAS is also currently conducting a Phase 1/2 open label basket study of GPS in combination with the anti-PD-1 therapy pembrolizumab in collaboration with Merck (known as MSD outside of the United States and Canada) in five indications: ovarian cancer (second or third line) and colorectal cancer (third or fourth line), which are the initial focus, to be followed by AML (patients unable to attain deeper morphological response than partial on hypomethylating agents and who are not eligible for allogeneic hematopoietic stem cell transplant), triple negative breast cancer (second line) and small cell lung cancer (second line). SELLAS has received Orphan Drug designations for GPS from the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for AML, malignant pleural mesothelioma (MPM), and multiple myeloma (MM). GPS has also received Fast Track designation for AML, MPM and MM from the FDA.

SELLAS’ second product candidate, nelipepimut-S (NPS), is an outlicensing opportunity as SELLAS is directing its resources to the development of GPS. NPS is a  HER2-directed cancer immunotherapy being investigated for the prevention of the recurrence of breast cancer after standard of care treatment in the adjuvant setting. NPS has received Fast Track status designation by FDA for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer (TNBC) patients, following standard of care.

SELLAS was founded in 2012 and its headquarters are in New York City.

Management

Portrait

Angelos M. Stergiou, M.D., Sc.D. h.c. , President & Chief Executive Officer

Dr. Angelos M. Stergiou is the founder, President and Chief Executive Officer of SELLAS Life Sciences Group, Inc. Prior to founding SELLAS in 2012, Dr. Stergiou co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company, where he served as President and Chief Operating Officer from 2009 to 2011. From 2002 to 2009, Dr. Stergiou held international positions of increasing responsibility in pharmaceutical and biotechnology companies, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International and Anavex Life Sciences. During this time, Dr. Stergiou held roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC).

Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including CNS, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe.

Dr. Stergiou was a member of the joint steering and oversight committee of PAION AG with Forest Laboratories, Inc. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology.

Dr. Stergiou holds a Doctor of Medicine from the U.S. American Institute of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry.

Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College, a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, a member of the American Academy of Physicians in Clinical Research, a member of the Association of Clinical Research Professionals, and a member of the New York Academy of Sciences.

Portrait

Dragan Cicic, MD , Senior Vice President, Clinical Development

Dr. Cicic is Senior Vice President of Clinical Development. Dr. Cicic has 20 years of experience in the biopharmaceutical industry. Before joining SELLAS, he was a Senior Vice President, Clinical Lead, at Klus Pharma, a wholly owned U.S. subsidiary of Kelun, a major China-based multinational pharmaceutical company with about 30,000 employees worldwide. At Klus Pharma, Dr. Cicic led the global clinical development of targeted solid cancer biologicals and was involved in the development of novel checkpoint inhibitors as well as other innovative biological and small molecule drug candidates.

Prior to Klus Pharma, Dr. Cicic held senior management positions at Actinium Pharmaceuticals where he launched key clinical trials, both early and late stage, in hematologic malignancies, primarily in acute myeloid leukemia. Dr. Cicic also worked with QED Technologies, a consulting company focused on life sciences. He received his medical degree from the University of Belgrade, and an MBA from the Wharton School of the University of Pennsylvania. Dr. Cicic also did a Fellowship at Harvard University. Dr. Cicic has published extensively in the fields of hematologic malignancies and solid cancers. He is a member of the American Society of Hematology (ASH).

Portrait

Barbara A. Wood , Executive Vice President, General Counsel and Corporate Secretary

Barbara Wood is Executive Vice President, General Counsel and Corporate Secretary. Ms. Wood has been practicing law for over 30 years. She was previously Senior Vice President, General Counsel and Corporate Secretary of Ophthotech Corporation (now known as IVERIC bio). Prior to joining Ophthotech, she spent 10 years at OSI Pharmaceuticals, Inc., where she was Senior Vice President, General Counsel and Secretary.

Before joining OSI, Ms. Wood was a partner at the New York firm of Squadron, Ellenoff, Plesent & Sheinfeld (now part of Hogan Lovells), focusing on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. While at Squadron Ellenoff, she also worked on transactions for some of the earliest biotech companies, representing an early biotech venture capitalist and angel investor. Ms. Wood received her law degree from Columbia Law School where she was a Harlan Fiske Stone Scholar and has a Bachelor of Arts (B.A.) degree in Economics and Classics from Connecticut College.

Portrait

John T. Burns, C.P.A. , Vice President Finance, Corporate Controller and Interim Principal Accounting Officer

John T. Burns is Vice President, Finance and Corporate Controller. Mr. Burns has over 10 years’ experience in finance and accounting. Mr. Burns joined the Company in May 2013 and has held various positions of increasing responsibility during his tenure, including the position of Vice President, Finance and Corporate Controller which he held since December 30, 2017. Prior to joining the Company, Mr. Burns was a Securities and Exchange Reporting Manager at Pixelworks, Inc. (NASDAQ: PSLW), and began his career in public accounting at Moss Adams LLP. Mr. Burns received a B.S.M. in Finance and Master of Accounting degree from Tulane University. He is an active Certified Public Accountant. On December 17, 2018, the Board of Directors of the Company appointed Mr. Burns as the Company’s interim principal accounting officer.

Board of Directors

Jane Wasman

Ms. Wasman was President, International & General Counsel and Corporate Secretary of Acorda Therapeutics, Inc. (NASDAQ: ACOR), a publicly traded biopharmaceutical company, from October 2012 to December 31, 2019, managing its International, Legal, Quality, IP and Compliance functions. From January 2012 until October 2012, she was Acorda’s Chief, Strategic Development, General Counsel and Corporate Secretary, and from May 2004 until January 2012, she was Acorda’s Executive Vice President, General Counsel and Corporate Secretary. Before joining Acorda, Ms. Wasman was with Schering-Plough Corporation, a global pharmaceutical company, for over eight years, holding various U.S. and international leadership positions, including Staff Vice President and Associate General Counsel. Ms. Wasman earned a J.D. from Harvard Law School and her undergraduate degree magna cum laude from Princeton University. She is a member of the Board of Directors of Rigel Pharmaceuticals (NASDAQ: RIGL), a publicly traded biotechnology company, and Cytovia Therapeutics, a private biotechnology company, and has been a member of the Board of Directors and of the executive committee of the Board of the New York Biotechnology Association since 2007.

David A. Scheinberg, M.D., Ph.D.

Dr. Scheinberg is currently Vincent Astor Chair, and Chairman, Molecular Pharmacology, Sloan Kettering Institute. He also founded and chairs the Center for Experimental Therapeutics at MSK, where he spearheaded the discovery and early clinical development of GPS, and founded and was chair of the Nanotechnology Center from 2010 to 2014. Additionally Dr. Scheinberg is a Professor of Medicine and Pharmacology and co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSK. Dr. Scheinberg is also an attending physician in the Department of Medicine, Leukemia Service and Hematology Laboratory Service/Department of Clinical Laboratories at Memorial Hospital. Dr. Scheinberg is an advisor to charitable foundations and cancer centers. Dr. Scheinberg is a member of the Board of Directors of Sapience Therapeutics, Inc., a privately held, preclinical stage biotechnology company, and was a member of the Board of Directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a publicly-traded biotechnology company, from 1996 to 2019, and Contrafect Corporation (NASDAQ: CFRX), a publicly traded clinical-stage biotechnology company, from 2010 to 2016. Dr. Scheinberg also served on SELLAS’ Scientific Advisory Board from 2015 through 2017. Dr. Scheinberg holds an M.D. and a Ph.D. in Pharmacology and Experimental Therapeutics from the Johns Hopkins University School of Medicine. Dr. Scheinberg earned his undergraduate degree in Biology from Cornell University.

Robert L. Van Nostrand

Mr. Van Nostrand is currently on the Board of Directors of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company, Yield10 Bioscience, Inc. (NASDAQ: YTEN), formerly Metabolix, Inc., a bio-agricultural company, and the Biomedical Research Alliance of New York, a private company providing clinical trial services. Mr. Van Nostrand was also on the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), a biotechnology company, until it was acquired in January 2020. Mr. Van Nostrand was Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc., a pathology life science company, from January 2010 to July 2010. Prior to joining Aureon Laboratories, Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, a private biotechnology company, from July 2007 to September 2008 when the company was acquired. Between 1986 and 2007, Mr. Van Nostrand held various executive and other management positions, including Chief Compliance Officer and Chief Financial Officer, at OSI Pharmaceuticals, Inc. Prior to joining OSI, Mr. Van Nostrand served in a managerial position with the accounting firm, Touche Ross & Co., currently Deloitte. Mr. Van Nostrand is also a member of the Board of Directors of the New York Biotechnology Association where he was the former chairman, and is on the Foundation Board of Farmingdale University. Mr. Van Nostrand holds a B.S. in Accounting from Long Island University and completed advanced management studies at the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.

John Varian

Mr. Varian served as Chief Executive Officer of XOMA Corporation, or XOMA, from August 2011 through December 2016 and served as a member of the Board of Directors of XOMA from December 2008 through May 2017. Mr. Varian served as a member of the Board of Directors of Versartis, Inc. (NASDAQ: VSAR), a publicly-traded biotechnology company, from March 2014 through October 2018, when it acquired Aravive, and the Board of Directors of Egalet Corporation (NASDAQ:EGLT), a publicly-traded biotechnology company, from June 2018 through February 2019, when it acquired the assets of Iroko. Mr. Varian previously served as Chief Operating Officer of ARYx Therapeutics, Inc. from December 2003 through August 2011. Beginning in May 2000, Mr. Varian was Chief Financial Officer of Genset S.A. in Paris France, where he was a key member of the team negotiating Genset’s sale to Serono S.A. in 2002. From 1998 to 2000, Mr. Varian served as Senior Vice President, Finance and Administration, of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation’s Chief Financial Officer from 1997 until 1998. From 1991 until 1997, Mr. Varian served as the VP Finance and Chief Financial Officer of Anergen Inc. Mr. Varian was an Audit Principal / Senior Manager at Ernst & Young LLP from 1987 until 1991 where he focused on life sciences. Mr. Varian was also a founding committee member of Bay Bio and a former chairman of the Association of Bioscience Financial Officers International Conference. Mr. Varian holds a B.B.A. from Western Michigan University. He is a Certified Public Accountant.

Angelos M. Stergiou, M.D., Sc.D. h.c.

Dr. Angelos M. Stergiou is the founder, President and Chief Executive Officer of SELLAS Life Sciences Group, Inc. Prior to founding SELLAS in 2012, Dr. Stergiou co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company, where he served as President and Chief Operating Officer from 2009 to 2011. From 2002 to 2009, Dr. Stergiou held international positions of increasing responsibility in pharmaceutical and biotechnology companies, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International and Anavex Life Sciences. During this time, Dr. Stergiou held roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC).

Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including CNS, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe.

Dr. Stergiou was a member of the joint steering and oversight committee of PAION AG with Forest Laboratories, Inc. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology.

Dr. Stergiou holds a Doctor of Medicine from the U.S. American Institute of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry.

Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College, a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, a member of the American Academy of Physicians in Clinical Research, a member of the Association of Clinical Research Professionals, and a member of the New York Academy of Sciences.

Scientific Advisory Board

Jeffrey Weber

Jeffrey Weber, MD, PHD - Chair

Jedd D. Wolchok

Jedd D. Wolchok,MD, PhD

Alexander

Alexander M.M. Eggermont,MD, PhD

Larry W. Kwak

Larry W. Kwak,MD, PHD

Javier Pinilla-Ibarz

Javier Pinilla-Ibarz,MD, PhD

Sattva Neelapu

Sattva Neelapu,MD, PHD

Guenther Koehne

Guenther Koehne,MD, PhD

Dr. Jeffrey Weber, a specialist in cancer immunotherapy, is currently deputy director of the Perlmutter Cancer Center and the co-director of the Melanoma Research Program at the New York University (NYU)-Langone Cancer Center. Dr. Weber is principal investigator on several ongoing studies funded by the National Cancer Institute (NCI) as well as industry, including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He earned his PhD in molecular biology from Rockefeller University (NY) in 1979 and his MD from New York University in 1980. Dr. Weber sat on the NCI’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He has published more than 180 articles in the top peer-reviewed journals in his field.

Prof. Alexander M.M. Eggermont is currently the Chief Scientific Officer of the Princess Maxima Center for Pediatric Oncology in Utrecht, The Netherlands, as well as Professor of Oncology at the University Paris-Sud and Professor of Oncological Surgery at the Erasmus University (Rotterdam). Prof. Eggermont has been Director General of Institut Gustave Roussy Cancer Campus Grand Paris, Villejuif, France, for nine years. He holds the honorary Chair of Surgical Oncology at the Catholic University of Louvain, Belgium. His past roles include being president of the European Cancer Organisation and European Organisation for Research and Treatment of Cancer (EORTC), the European Cancer Organisation (ECCO), and the European Academy of Cancer Sciences (EACS), Chair of the EORTC Melanoma Group, as well as board member of the European Society for Medical Oncology (ESMO). In Germany, Prof. Eggermont is closely involved in the program organizing a network of comprehensive cancer centers and holds a partial position at the German Cancer Research Center (DKFZ) in Heidelberg. He is editor-in-chief of the European Journal of Cancer. He obtained his MD at the University of Amsterdam and PhD in tumor immunology at the Erasmus University in Rotterdam, both in the Netherlands, and was a Fellow of the National Cancer Institute (NCI) Surgery Branch in Bethesda, MD, USA. He has published more than 800 peer reviewed publications.

Dr. Guenther Koehne is Chief of Bone Marrow Transplantation and Hematologic Oncology at the Miami Cancer Institute, part of Baptist Health South Florida, in Miami, Florida. Prior to assuming this role in mid-2017, he was an Attending Physician of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center (MSKCC) and also held the position of Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at MSKCC since 2010. He was Associate Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service at MSKCC from 2007 to 2014, as well as Associate Professor of Medicine of the Weill Cornell Medical College of Cornell University from 2007 to 2017. Dr. Koehne has led fundamental research in the mechanisms of immunologic response to multiple myeloma antigens and has spearheaded the development of innovative adoptive immunotherapeutic strategies for post-transplant blood disorders, including plasma cell dyscrasias. Dr. Koehne has particular expertise in the creation and monitoring of antigen-specific T-cell responses in these patients. He is the Principal Investigator in active clinical trials using adoptive cell therapy following allogeneic stem cell transplants for multiple myeloma and plasma cell leukemia patients. Dr. Koehne graduated with his MD in 1991 from the Medical University of Hamburg in Germany and received his PhD from the same institution in 1996. He completed residencies at the Medical University of Hamburg General Hospital and Rush University Medical Center in Chicago, before undertaking his fellowship training at MSKCC and Weill Cornell Medical College in New York. Dr. Koehne is board certified in both Internal Medicine and Medical Oncology, and keeps up to date with the latest advances in his field by maintaining a professional membership with the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation. Dr. Koehne has published more than 70 peer-reviewed journal articles, textbook chapters and monographs.

Dr. Larry W. Kwak is Vice President and Deputy Director of the City of Hope Comprehensive Cancer Center in Duarte, CA. He is also Associate Director, Translational Research & Developmental Therapeutics for the City of Hope National Medical Center, Director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute, and is endowed with the title of the Dr. Michael Friedman Professor in Translational Medicine. From 2004 to 2014, Dr. Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, where he also held the Jane and John Justin Distinguished Chair in Leukemia Research. Prior to his role at M.D. Anderson, Dr. Kwak served as Head of the Vaccine Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute (NCI) for 12 years. His laboratory at the NCI was credited with the bench-to-clinic development of a therapeutic cancer vaccine for B-cell malignancies. In 2010, Dr. Kwak was named to TIME Magazine’s TIME100 as one of the world’s 100 most influential people for his 20-year commitment to the science of cancer vaccines, specifically a personalized therapy for follicular lymphoma. He is an elected member of the Association of American Physicians (AAP). Dr. Kwak received his medical degree from Northwestern University Medical School and earned his Ph.D. in tumor cell biology there in 1984. He also completed a residency in internal medicine and a fellowship in medical oncology at Stanford University Medical Center in California. He has authored more than 200 peer-reviewed publications, book chapters and monographs.

Dr. Sattva Neelapu serves as a Professor and Deputy Department Chair at the Department of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas M.D. Anderson Cancer Center in Houston, TX.

Dr. Neelapu’s laboratory is focused on characterization of immune-regulatory mechanisms in the tumor microenvironment in patients with lymphoma and development of novel therapeutic strategies for patients with lymphoma. Dr. Neelapu’s clinical research has focused on the development of therapeutic vaccines for lymphoid malignancies and he has conducted some of the first immune checkpoint inhibitor trials in lymphoma. Most recently, his work on the pivotal trial of axicabtagene ciloleucel CD 19 CAR T-cell therapy in aggressive B-cell lymphoma led to its FDA approval as the first CAR-T therapy for lymphoma. His research is supported and recognized by numerous awards from national and international organizations including the National Institutes of Health, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, Doris Duke Charitable Foundation, and Leukemia and Lymphoma Society. Dr. Neelapu has been also awarded the Outstanding Achievement Award by the Indo-American Cancer Association (IACA), as well as the Excellence in Oncology Award by Oncology Times.

Dr. Neelapu obtained his medical degree in India and subsequently moved to the United States where he completed residency in Internal Medicine at Coney Island Hospital, Brooklyn, New York, and a clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute (NCI) in Bethesda, Maryland. Dr. Neelapu has published more than 200 peer reviewed journal articles, textbook chapters and monographs.

Dr. Javier Pinilla-Ibarz is currently a senior member of the malignant hematology and immunology program and Director of Immunotherapy for Malignant Hematology at the H. Lee Moffitt Cancer Center, as well as Professor in the Department of Oncologic Sciences, University of South Florida College of Medicine, both in Tampa, Florida. He has a long track record of successfully applying immunology clinical and translational approaches to the treatment of leukemias and myelodysplastic syndromes, and has participated in several clinical trials of peptide and cellular vaccines in various hematological disorders, including acute and chronic leukemias. Dr. Pinilla-Ibarz received his MD and PhD degrees from the University of Zaragoza, Spain. He then completed a research fellowship in Immunology at the Memorial Sloan-Kettering Cancer Center (MSKCC), as well as Hematology and Oncology training at the same Institution. Dr. Pinilla-Ibarz has published more than 130 articles in top peer-reviewed journals in his field.

Dr. Jeffrey Weber, a specialist in cancer immunotherapy, is currently deputy director of the Perlmutter Cancer Center and the co-director of the Melanoma Research Program at the New York University (NYU)-Langone Cancer Center. Dr. Weber is principal investigator on several ongoing studies funded by the National Cancer Institute (NCI) as well as industry, including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He earned his PhD in molecular biology from Rockefeller University (NY) in 1979 and his MD from New York University in 1980. Dr. Weber sat on the NCI’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He has published more than 150 articles in the top peer-reviewed journals in his field.

Dr. Jedd D. Wolchok is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSKCC), an associate director of the Ludwig Center for Cancer Immunotherapy at MSKCC, an associate member of Ludwig Cancer Research, and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at MSKCC in New York. He is director of the CRI/Ludwig Cancer Vaccine Collaborative Trials Network, and is an associate director of the CRI Scientific Advisory Council. He is also the co-director of the Swim Across America laboratory at MSKCC, one of the foremost immunotherapy and melanoma research groups in the country.

His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma.

Dr. Wolchok has more than 350 papers in peer-reviewed journals, among which seminal articles concerning DNA vaccines, cytokine biology, and clinical care of melanoma and co-authored two chapters in the definitive textbook, Cutaneous Melanoma. Dr. Wolchok is also academic editor of the Journal of Experimental Medicine and co-editor of the journal Cytotherapy.